Jazz Pharmaceuticals/$JAZZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
2,800
ISIN
IE00B4Q5ZN47
Website
JAZZ Metrics
BasicAdvanced
$6.5B
14.23
$7.51
0.38
-
Price and volume
Market cap
$6.5B
Beta
0.38
52-week high
$148.06
52-week low
$95.49
Average daily volume
802K
Financial strength
Current ratio
3.376
Quick ratio
2.638
Long term debt to equity
128.752
Total debt to equity
129.495
Interest coverage (TTM)
2.20%
Profitability
EBITDA (TTM)
1,392.039
Gross margin (TTM)
92.15%
Net profit margin (TTM)
11.86%
Operating margin (TTM)
17.97%
Effective tax rate (TTM)
-33.47%
Revenue per employee (TTM)
$1,450,000
Management effectiveness
Return on assets (TTM)
3.99%
Return on equity (TTM)
12.25%
Valuation
Price to earnings (TTM)
14.229
Price to revenue (TTM)
1.616
Price to book
1.58
Price to tangible book (TTM)
-2.83
Price to free cash flow (TTM)
4.413
Free cash flow yield (TTM)
22.66%
Free cash flow per share (TTM)
2,422.22%
Growth
Revenue change (TTM)
5.76%
Earnings per share change (TTM)
49.21%
3-year revenue growth (CAGR)
7.19%
10-year revenue growth (CAGR)
12.65%
3-year earnings per share growth (CAGR)
0.64%
10-year earnings per share growth (CAGR)
8.02%
What the Analysts think about JAZZ
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
Bulls say / Bears say
Jazz Pharmaceuticals' drug Xywav remains the preferred low-sodium oxybate therapy for narcolepsy treatment, indicating strong market positioning. (Investing.com)
Epidiolex is nearing blockbuster status with annual revenues exceeding $900 million, showcasing significant growth potential. (Investing.com)
The company forecasts 2024 revenues to be in the range of $4 billion to $4.2 billion, reflecting confidence in its growth trajectory. (Investing.com)
Jazz Pharmaceuticals agreed to pay $145 million to settle claims related to delaying a generic version of its narcolepsy drug Xyrem, which could impact financials. (Reuters)
The company noted an increase in programs leveraging their affordability options, which is expected to decline as the programs are refined, potentially affecting future revenues. (Investing.com)
There are potential challenges with the drug Tarlatamab due to its safety profile, which could hinder its market acceptance. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
JAZZ Financial Performance
Revenues and expenses
JAZZ Earnings Performance
Company profitability
JAZZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $6.5B as of June 30, 2025.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 14.23 as of June 30, 2025.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.